- Home
- FFNW vs TIL Comparison
FFNW vs TIL Comparison
Compare FFNW & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFNW
- TIL
- Stock Information
- Founded
- FFNW 1923
- TIL 2018
- Country
- FFNW United States
- TIL United States
- Employees
- FFNW N/A
- TIL N/A
- Industry
- FFNW Banks
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- FFNW Finance
- TIL Health Care
- Exchange
- FFNW Nasdaq
- TIL Nasdaq
- Market Cap
- FFNW 203.8M
- TIL 171.7M
- IPO Year
- FFNW N/A
- TIL 2021
- Fundamental
- Price
- FFNW $21.43
- TIL $22.12
- Analyst Decision
- FFNW Hold
- TIL Strong Buy
- Analyst Count
- FFNW 2
- TIL 4
- Target Price
- FFNW $22.75
- TIL $114.00
- AVG Volume (30 Days)
- FFNW 17.6K
- TIL 83.9K
- Earning Date
- FFNW 01-28-2025
- TIL 03-20-2025
- Dividend Yield
- FFNW 1.21%
- TIL N/A
- EPS Growth
- FFNW N/A
- TIL N/A
- EPS
- FFNW 0.12
- TIL N/A
- Revenue
- FFNW $37,609,000.00
- TIL N/A
- Revenue This Year
- FFNW N/A
- TIL N/A
- Revenue Next Year
- FFNW $0.82
- TIL N/A
- P/E Ratio
- FFNW $183.59
- TIL N/A
- Revenue Growth
- FFNW N/A
- TIL N/A
- 52 Week Low
- FFNW $20.10
- TIL $9.62
- 52 Week High
- FFNW $23.50
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- FFNW 50.18
- TIL 48.67
- Support Level
- FFNW $21.32
- TIL $19.00
- Resistance Level
- FFNW $21.61
- TIL $25.80
- Average True Range (ATR)
- FFNW 0.23
- TIL 2.19
- MACD
- FFNW 0.01
- TIL 0.22
- Stochastic Oscillator
- FFNW 54.43
- TIL 45.88
About FFNW First Financial Northwest Inc.
First Financial Northwest Inc is the holding company. The Bank's business consists predominantly of attracting deposits from the general public, combined with borrowing from the FHLB of Des Moines and raising funds in the wholesale market then utilizing these funds to originate one-to-four family residential, multifamily, commercial real estate, construction/land, business, and consumer loans. The Bank's strategic initiatives seek to diversify its loan portfolio and broaden growth opportunities with its current risk tolerance levels and asset/liability objectives.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.